MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

Search

Stevanato Group SpA

Aperta

SettoreSettore sanitario

20.42 -1.35

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

20.4

Massimo

20.87

Metriche Chiave

By Trading Economics

Entrata

10M

49M

Vendite

23M

303M

P/E

Media del settore

35.083

87.826

EPS

0.162

Rendimento da dividendi

0.26

Margine di Profitto

16.205

Dipendenti

5,521

EBITDA

10M

73M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+23.18% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.26%

2.26%

Utili prossimi

5 mar 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-991M

5.7B

Apertura precedente

21.77

Chiusura precedente

20.42

Notizie sul Sentiment di mercato

By Acuity

50%

50%

173 / 370 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Stevanato Group SpA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 gen 2026, 23:54 UTC

Discorsi di Mercato

CBA Could Underperform Again in 2026 -- Market Talk

12 gen 2026, 23:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

12 gen 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Weaker Yen -- Market Talk

12 gen 2026, 23:43 UTC

Discorsi di Mercato

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 gen 2026, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 gen 2026, 21:56 UTC

Discorsi di Mercato

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 gen 2026, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

12 gen 2026, 21:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

12 gen 2026, 21:18 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

12 gen 2026, 21:18 UTC

Discorsi di Mercato

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 gen 2026, 20:54 UTC

Utili

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 gen 2026, 20:48 UTC

Discorsi di Mercato

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 gen 2026, 20:33 UTC

Discorsi di Mercato

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 gen 2026, 20:18 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 gen 2026, 20:18 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 gen 2026, 19:39 UTC

Discorsi di Mercato

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 gen 2026, 19:36 UTC

Discorsi di Mercato

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 gen 2026, 19:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

12 gen 2026, 19:33 UTC

Discorsi di Mercato

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 gen 2026, 19:24 UTC

Acquisizioni, Fusioni, Takeovers

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 gen 2026, 19:22 UTC

Acquisizioni, Fusioni, Takeovers

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 gen 2026, 18:21 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 gen 2026, 18:20 UTC

Acquisizioni, Fusioni, Takeovers

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 gen 2026, 18:19 UTC

Discorsi di Mercato

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 gen 2026, 18:16 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 gen 2026, 18:09 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

12 gen 2026, 18:09 UTC

Discorsi di Mercato

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 gen 2026, 18:01 UTC

Acquisizioni, Fusioni, Takeovers

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 gen 2026, 18:00 UTC

Discorsi di Mercato

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Confronto tra pari

Modifica del prezzo

Stevanato Group SpA Previsione

Obiettivo di Prezzo

By TipRanks

23.18% in crescita

Previsioni per 12 mesi

Media 27 USD  23.18%

Alto 30 USD

Basso 24 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Stevanato Group SpA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

21.56 / 22.61Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

173 / 370 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Stevanato Group SpA

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
help-icon Live chat